Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation

Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical o...

Descripción completa

Detalles Bibliográficos
Autores: Bejanyan, Nelli|||0000-0003-0194-7338, Zhang, Mei-Jie, Wang, Hai-Lin, Lazaryan, Aleksandr, de Lima, Marcos|||0000-0002-8568-4522, Marks, David I., Sandmaier, Brenda M.|||0000-0002-9767-9739, Bachanova, Veronika, Rowe, Jacob, Tallman, Martin, Kebriaei, Partow|||0000-0002-8607-9404, Kharfan-Dabaja, Mohamed|||0000-0001-7394-5185, Peter Gale, Robert, Lazarus, Hillard M.|||0000-0002-1159-5607, Ustun, Celalettin|||0000-0001-6896-6213, Copelan, Edward, Ky Hamilton, Betty, Schiller, Gary, Hogan, Willian, Hashmi, Shahrukh, Seftel, Matthew, Kanakry, Christopher G., Olsson, Richard F., Martino Bofarull, Rodrigo|||0000-0001-5143-4042, Saber, Wael, Khoury, H.Jean, Weisdorf, Daniel J.
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:286918
Acceso en línea:https://ddd.uab.cat/record/286918
https://dx.doi.org/urn:doi:10.1016/j.bbmt.2017.12.784
Access Level:acceso abierto
Palabra clave:ALL
Allogeneic transplant
Consolidation chemotherapy
Myeloablative conditioning
Descripción
Sumario:Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving ≥2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values.

Similares en LA Referencia